摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-[2-(2,3-Dihydro-1H-indol-1-yl)phenyl]-4-methyl-1-piperazinecarboxamide Maleate

中文名称
——
中文别名
——
英文名称
N-[2-(2,3-Dihydro-1H-indol-1-yl)phenyl]-4-methyl-1-piperazinecarboxamide Maleate
英文别名
(Z)-but-2-enedioic acid;N-[2-(2,3-dihydroindol-1-yl)phenyl]-4-methylpiperazine-1-carboxamide
N-[2-(2,3-Dihydro-1H-indol-1-yl)phenyl]-4-methyl-1-piperazinecarboxamide Maleate化学式
CAS
——
化学式
C4H4O4*C20H24N4O
mdl
——
分子量
452.51
InChiKey
BQFHDWFKSIKXTK-BTJKTKAUSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.87
  • 重原子数:
    33
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.29
  • 拓扑面积:
    113
  • 氢给体数:
    3
  • 氢受体数:
    7

反应信息

  • 作为产物:
    描述:
    N-(2-aminophenyl)indoline三乙胺4-甲基哌嗪-1-甲酰氯盐酸盐顺丁烯二酸氮气Sodium sulfate-III乙醇 作用下, 以 氯仿乙醇 为溶剂, 反应 47.33h, 以to afford 19.2 g (43%)的产率得到N-[2-(2,3-Dihydro-1H-indol-1-yl)phenyl]-4-methyl-1-piperazinecarboxamide Maleate
    参考文献:
    名称:
    Benzopyrrolobenzodiazepines and quinobenzodiazepines useful for the
    摘要:
    本发明涉及式子##STR1##的苯并吡咯苯并二氮杂环己烷和喹诺苯并二氮杂环己烷,其中X和Y可以相同或不同,每个都是氢,卤素,CF.sub.3,低烷基,低烷氧基,低烷硫基和低烷基磺酰基,p和q独立地为1或2;当R.sub.2与R.sub.3连接形成--(CH.sub.2).sub.m --CH.sub.2--基团或--CH.dbd.CH--基团时,R.sub.1为氢;当R.sub.1与R.sub.2连接形成--(CH.sub.2).sub.m --CH.sub.2--基团或--CH.dbd.CH--基团时,R.sub.3为氢; m为1或2; R.sub.4为NR.sub.5R.sub.6,其中R.sub.5为氢或低烷基,R.sub.6为氢,低烷基或(CH.sub.2).sub.n NR.sub.7R.sub.8基团,其中R.sub.7和R.sub.8为低烷基,n为2或3,##STR2##其中R.sub.9为低烷基,##STR3##其中R.sub.10为CH.sub.2CH.sub.2OH,低烷基,苯基,被卤素,CF.sub.3,低烷基,低烷氧基或低烷硫基取代的苯基,苄基,被卤素,CF.sub.3,低烷基,低烷氧基或低烷硫基取代的苄基或CO.sub.2R.sub.11,其中R.sub.11为低烷基,或其药学上可接受的酸盐。
    公开号:
    US04761412A1
点击查看最新优质反应信息

文献信息

  • Benzo[b]pyrrolo[3,2,1-jk][1,4]benzodiazepines having dopamine receptor
    申请人:Hoechst-Roussel Pharmaceuticals Inc.
    公开号:US04663453A1
    公开(公告)日:1987-05-05
    The invention relates to benzopyrrolobenzodiazepines and quinobenzodiazepines of the formula ##STR1## where X and Y may be the same or different and each is hydrogen, halogen, CF.sub.3, lower alkyl, lower alkoxy, lower alkylthio and lower alkylsulfonyl, p and q are independently 1 or 2; R.sub.1 is hydrogen when R.sub.2 is bonded to R.sub.3 to form a --(CH.sub.2).sub.m --CH.sub.2 -- group or a --CH.dbd.CH-- group; R.sub.3 is hydrogen when R.sub.1 is bonded to R.sub.2 to form a --(CH.sub.2).sub.m --CH.sub.2 -- group or a --CH.dbd.CH-- group; m is 1 or 2; R.sub.4 is NR.sub.5 R.sub.6 wherein R.sub.5 is hydrogen or lower alkyl and R.sub.6 is hydrogen, lower alkyl or a group of the formula (CH.sub.2).sub.n NR.sub.7 R.sub.8 wherein R.sub.7 and R.sub.8 are lower alkyl, and n is 2 or 3, ##STR2## wherein R.sub.9 is lower alkyl, ##STR3## wherein R.sub.10 is CH.sub.2 CH.sub.2 OH, lower alkyl, phenyl, phenyl substituted by halogen, CF.sub.3, lower alkyl, lower alkoxy or lower alkylthio, benzyl, benzyl in which the phenyl group is substituted by halogen, CF.sub.3, lower alkyl, lower alkoxy or lower alkylthio or CO.sub.2 R.sub.11 wherein R.sub.11 is lower alkyl, or a pharmaceutically acceptable acid salt thereof.
    本发明涉及式为##STR1##的苯并吡咯苯并二氮杂环己烷和喹诺苯并二氮杂环己烷,其中X和Y可以相同也可以不同,每个都是氢、卤素、CF.sub.3、低烷基、低烷氧基、低烷硫基和低烷基磺酰基,p和q是独立的1或2;当R.sub.2与R.sub.3结合形成--(CH.sub.2).sub.m --CH.sub.2 --基团或--CH.dbd.CH--基团时,R.sub.1为氢;当R.sub.1与R.sub.2结合形成--(CH.sub.2).sub.m --CH.sub.2 --基团或--CH.dbd.CH--基团时,R.sub.3为氢;m为1或2;R.sub.4为NR.sub.5 R.sub.6,其中R.sub.5为氢或低烷基,R.sub.6为氢、低烷基或(CH.sub.2).sub.n NR.sub.7 R.sub.8的基团,其中R.sub.7和R.sub.8为低烷基,n为2或3,##STR2##其中R.sub.9为低烷基,##STR3##其中R.sub.10为CH.sub.2 CH.sub.2 OH、低烷基、苯基、卤代苯基、CF.sub.3、低烷氧基或低烷硫基的取代苯基、苄基、卤代苄基、CF.sub.3、低烷氧基或低烷硫基的取代苄基或CO.sub.2 R.sub.11,其中R.sub.11为低烷基,或其药学上可接受的酸盐。
  • Benzopyrrolobenzodiazepines and quinobenzodiazepines
    申请人:Hoechst-Roussel Pharmaceuticals Inc.
    公开号:US04723007A1
    公开(公告)日:1988-02-02
    The invention relates to benzopyrrolobenzodiazepines and quinobenzodiazepines of the formula ##STR1## where X and Y may be the same or different and each is hydrogen, halogen, CF.sub.3, lower alkyl, lower alkoxy, lower alkylthio and lower alkylsulfonyl, p and q are independently 1 or 2; R.sub.1 is hydrogen when R.sub.2 is bonded to R.sub.3 to form a --(CH.sub.2).sub.m --CH.sub.2 -- group or a --CH.dbd.CH-- group; R.sub.3 is hydrogen when R.sub.1 is bonded to R.sub.2 to form a --(CH.sub.2).sub.m --CH.sub.2 -- group or a --CH.dbd.CH-- group; m is 1 or 2; R.sub.4 is NR.sub.5 R.sub.6 wherein R.sub.5 is hydrogen or lower alkyl and R.sub.6 is hydrogen, lower alkyl or a group of the formula (CH.sub.2).sub.n NR.sub.7 R.sub.8 wherein R.sub.7 and R.sub.8 are lower alkyl, and n is 2 or 3, ##STR2## wherein R.sub.9 is lower alkyl, ##STR3## wherein R.sub.10 is CH.sub.2 CH.sub.2 OH, lower alkyl, phenyl, phenyl substituted by halogen, CF.sub.3, lower alkyl, lower alkoxy or lower alkylthio, benzyl, benzyl in which the phenyl group is substituted by halogen, CF.sub.3, lower alkyl, lower alkoxy or lower alkylthio or CO.sub.2 R.sub.11 wherein R.sub.11 is lower alkyl, or a pharmaceutically acceptable acid salt thereof.
    本发明涉及公式##STR1##中的苯并吡咯苯并二氮杂环和喹诺苯并二氮杂环,其中X和Y可以相同也可以不同,每个都是氢、卤素、CF.sub.3、低烷基、低烷氧基、低烷硫基和低烷基磺酰基,p和q独立地为1或2; 当R.sub.2与R.sub.3结合形成--(CH.sub.2).sub.m --CH.sub.2--基团或--CH.dbd.CH--基团时,R.sub.1为氢; 当R.sub.1与R.sub.2结合形成--(CH.sub.2).sub.m --CH.sub.2--基团或--CH.dbd.CH--基团时,R.sub.3为氢; m为1或2; R.sub.4为NR.sub.5R.sub.6,其中R.sub.5为氢或低烷基,R.sub.6为氢、低烷基或(CH.sub.2).sub.nNR.sub.7R.sub.8的基团,其中R.sub.7和R.sub.8为低烷基,n为2或3,##STR2##其中R.sub.9为低烷基,##STR3##其中R.sub.10为CH.sub.2CH.sub.2OH、低烷基、苯基、被卤素、CF.sub.3、低烷基氧基或低烷硫基取代的苯基、苄基、苄基中苯基被卤素、CF.sub.3、低烷基氧基或低烷硫基取代或CO.sub.2R.sub.11,其中R.sub.11为低烷基,或其药学上可接受的酸盐。
  • Benzopyrrolobenzodiazepines and quinobenzodiazepines useful for the
    申请人:Hoechst-Roussel Pharmaceuticals Inc.
    公开号:US04761412A1
    公开(公告)日:1988-08-02
    The invention relates to benzopyrrolobenzodiazepines and quinobenzodiazepines of the formula ##STR1## where X and Y may be the same or different and each is hydrogen, halogen, CF.sub.3, lower alkyl, lower alkoxy, lower alkylthio and lower alkylsulfonyl, p and q are independently 1 or 2; R.sub.1 is hydrogen when R.sub.2 is bonded to R.sub.3 to form a --(CH.sub.2).sub.m --CH.sub.2 -- group or a --CH.dbd.CH-- group; R.sub.3 is hydrogen when R.sub.1 is bonded to R.sub.2 to form a --(CH.sub.2).sub.m --CH.sub.2 -- group or a --CH.dbd.CH-- group; m is 1 or 2; R.sub.4 is NR.sub.5 R.sub.6 wherein R.sub.5 is hydrogen or lower alkyl and R.sub.6 is hydrogen, lower alkyl or a group of the formula (CH.sub.2).sub.n NR.sub.7 R.sub.8 wherein R.sub.7 and R.sub.8 are lower alkyl, and n is 2 or 3, ##STR2## wherein R.sub.9 is lower alkyl, ##STR3## wherein R.sub.10 is CH.sub.2 CH.sub.2 OH, lower alkyl, phenyl, phenyl substituted by halogen, CF.sub.3, lower alkyl, lower alkoxy or lower alkylthio, benzyl, benzyl in which the phenyl group is substituted by halogen, CF.sub.3, lower alkyl, lower alkoxy or lower alkylthio or CO.sub.2 R.sub.11 wherein R.sub.11 is lower alkyl, or a pharmaceutically acceptable acid salt thereof.
    本发明涉及式子##STR1##的苯并吡咯苯并二氮杂环己烷和喹诺苯并二氮杂环己烷,其中X和Y可以相同或不同,每个都是氢,卤素,CF.sub.3,低烷基,低烷氧基,低烷硫基和低烷基磺酰基,p和q独立地为1或2;当R.sub.2与R.sub.3连接形成--(CH.sub.2).sub.m --CH.sub.2--基团或--CH.dbd.CH--基团时,R.sub.1为氢;当R.sub.1与R.sub.2连接形成--(CH.sub.2).sub.m --CH.sub.2--基团或--CH.dbd.CH--基团时,R.sub.3为氢; m为1或2; R.sub.4为NR.sub.5R.sub.6,其中R.sub.5为氢或低烷基,R.sub.6为氢,低烷基或(CH.sub.2).sub.n NR.sub.7R.sub.8基团,其中R.sub.7和R.sub.8为低烷基,n为2或3,##STR2##其中R.sub.9为低烷基,##STR3##其中R.sub.10为CH.sub.2CH.sub.2OH,低烷基,苯基,被卤素,CF.sub.3,低烷基,低烷氧基或低烷硫基取代的苯基,苄基,被卤素,CF.sub.3,低烷基,低烷氧基或低烷硫基取代的苄基或CO.sub.2R.sub.11,其中R.sub.11为低烷基,或其药学上可接受的酸盐。
  • Dibenzodiazepin derivatives, a process for their preparation and their use as medicaments
    申请人:HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED
    公开号:EP0129692A2
    公开(公告)日:1985-01-02
    The invention relates to dihydrobenzopyrrolobenzodiazepines of the formula where X and Y may be the same or different and each is hydrogen, halogen, CF., lower alkoxy, lower alkylthio and lower alkylsulfonyl; R, is hydrogen when R2 is bonded to R3 to form a -(CH2)m-CH2-group or a -CH=CH-group; R3 is hydrogen when R, is bonded to R. to form a -(CH2)m-CH2- group or a -CH-CH- group; and R4 is NR5R6 wherein R. is hydrogen or lower alkyl and R6 is hydrogen, lower alkyl or a group of the formula (CH2)nNR7R8 wherein R7 and R. are lower alkyl, m is 1 or 2 and n is 2 or 3, wherein R. is lower alkyl, or wherein R10 is lower alkyl, phenyl, phenyl substituted by halogen, CF3, lower alkyl, lower alkoxy or lower alkylthio, benzyl, benzyl in which the phenyl group is substituted by halogen, CF3, lower alkyl, lower alkoxy or lower alkylthio or CO2R11, wherein R11 is lower alkyl, or a pharmaceutically acceptable acid salt thereof.
    本发明涉及式如下的二氢吡咯并二氮杂卓 式中 X 和 Y 可以相同或不同,各自为氢、卤素、CF、当 R2 与 R3 键合形成-(CH2)m-CH2-基团或-CH=CH-基团时,R3 为氢;当 R2 与 R3 键合形成-(CH2)m-CH2-基团或-CH=CH-基团时,R3 为氢。和 R4 是 NR5R6,其中 R. 是氢或低级烷基,R6 是氢、低级烷基或式 (CH2)nNR7R8 的基团,其中 R7 和 R. 是低级烷基,m 是 1 或 2,n 是 2 或 3、 其中 R. 为低级烷基 或 其中 R10 为低级烷基、苯基、被卤素、CF3、低级烷基、低级烷氧基或低级烷硫基取代的苯基、苄基、苯基被卤素、CF3、低级烷基、低级烷氧基或低级烷硫基取代的苄基或 CO2R11(其中 R11 为低级烷基)或其药学上可接受的酸盐。
  • US4663453A
    申请人:——
    公开号:US4663453A
    公开(公告)日:1987-05-05
查看更多

同类化合物

(N-(2-甲基丙-2-烯-1-基)乙烷-1,2-二胺) (4-(苄氧基)-2-(哌啶-1-基)吡啶咪丁-5-基)硼酸 (11-巯基十一烷基)-,,-三甲基溴化铵 鼠立死 鹿花菌素 鲸蜡醇硫酸酯DEA盐 鲸蜡硬脂基二甲基氯化铵 鲸蜡基胺氢氟酸盐 鲸蜡基二甲胺盐酸盐 高苯丙氨醇 高箱鲀毒素 高氯酸5-(二甲氨基)-1-({(E)-[4-(二甲氨基)苯基]甲亚基}氨基)-2-甲基吡啶正离子 高氯酸2-氯-1-({(E)-[4-(二甲氨基)苯基]甲亚基}氨基)-6-甲基吡啶正离子 高氯酸2-(丙烯酰基氧基)-N,N,N-三甲基乙铵 马诺地尔 马来酸氢十八烷酯 马来酸噻吗洛尔EP杂质C 马来酸噻吗洛尔 马来酸倍他司汀 顺式环己烷-1,3-二胺盐酸盐 顺式氯化锆二乙腈 顺式吡咯烷-3,4-二醇盐酸盐 顺式双(3-甲氧基丙腈)二氯铂(II) 顺式3,4-二氟吡咯烷盐酸盐 顺式1-甲基环丙烷1,2-二腈 顺式-二氯-反式-二乙酸-氨-环己胺合铂 顺式-二抗坏血酸(外消旋-1,2-二氨基环己烷)铂(II)水合物 顺式-N,2-二甲基环己胺 顺式-4-甲氧基-环己胺盐酸盐 顺式-4-环己烯-1.2-二胺 顺式-4-氨基-2,2,2-三氟乙酸环己酯 顺式-2-甲基环己胺 顺式-2-(苯基氨基)环己醇 顺式-2-(氨基甲基)-1-苯基环丙烷羧酸盐酸盐 顺式-1,3-二氨基环戊烷 顺式-1,2-环戊烷二胺 顺式-1,2-环丁腈 顺式-1,2-双氨甲基环己烷 顺式--N,N'-二甲基-1,2-环己二胺 顺式-(R,S)-1,2-二氨基环己烷铂硫酸盐 顺式-(2-氨基-环戊基)-甲醇 顺-2-戊烯腈 顺-1,3-环己烷二胺 顺-1,3-双(氨甲基)环己烷 顺,顺-丙二腈 非那唑啉 靛酚钠盐 靛酚 霜霉威盐酸盐 霜脲氰